LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• LifeMD has a “Moderate Buy” consensus rating from 10 brokerages: eight buys, one hold and one sell. The average 12-month price target is $7.57.
• Shares opened at $3.08, well below the analyst average target, with a one-year range of $2.56 to $7.32 and a market capitalization of approximately $148.5 million.
• LifeMD reported a quarterly loss of $0.16 per share, slightly worse than the expected $0.15 loss, while revenue of $47.28 million fell short of the $49.16 million consensus estimate.

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $7.5714.

A number of analysts recently weighed in on the company. KeyCorp set a $5.00 price objective on LifeMD and gave the company an "overweight" rating in a report on Friday, August 7th. HC Wainwright cut their target price on LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Lake Street Capital set a $5.00 price target on LifeMD in a research report on Thursday, August 6th. Wall Street Zen cut LifeMD from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. Finally, B. Riley Financial decreased their price target on LifeMD from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, August 6th.

LifeMD Price Performance

NASDAQ:LFMD opened at $3.08 on Tuesday. The firm's 50 day simple moving average is $3.79 and its 200 day simple moving average is $3.98. LifeMD has a one year low of $2.56 and a one year high of $7.32. The company has a market cap of $148.46 million, a PE ratio of -61.59 and a beta of 2.04.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.01). The business had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. Equities research analysts expect that LifeMD will post -0.46 EPS for the current year.

Institutional Trading of LifeMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in shares of LifeMD by 8.0% in the 2nd quarter. BlackRock Inc. now owns 3,034,535 shares of the company's stock worth $12,533,000 after purchasing an additional 225,510 shares during the period. Vanguard Group Inc. boosted its position in LifeMD by 6.7% during the third quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company's stock valued at $15,120,000 after acquiring an additional 140,749 shares during the last quarter. Federated Hermes Inc. grew its holdings in LifeMD by 278.1% during the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company's stock worth $3,343,000 after acquiring an additional 721,018 shares during the period. Geode Capital Management LLC raised its position in shares of LifeMD by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 959,700 shares of the company's stock worth $3,273,000 after acquiring an additional 11,324 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in shares of LifeMD by 11.7% in the 4th quarter. Royce & Associates LP now owns 909,651 shares of the company's stock valued at $3,102,000 after purchasing an additional 95,200 shares during the period. Institutional investors and hedge funds own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.